Drug Profile


Alternative Names: EDP-103; KHK-2375; MS-27-275; MS-275; SNDX-275

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Nihon Schering; Pfizer; University of Tokyo
  • Developer Eddingpharm; Genentech; Kyowa Hakko Kirin; Merck & Co; National Cancer Institute (USA); Roswell Park Cancer Institute; Syndax Pharmaceuticals
  • Class Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Hodgkin's disease; Leukaemia; Non-small cell lung cancer
  • Phase I/II Malignant melanoma; Renal cell carcinoma
  • No development reported Colorectal cancer

Most Recent Events

  • 14 Dec 2016 Syndax Pharmaceuticals establishes CRADA with National Cancer Institute for the development of Entinostat and UCB 6352 and in Cancer
  • 17 Oct 2016 The National Cancer Institute plans a phase Ib trial for Myelodysplastic syndromes (Second-line therapy or greater, Combination therapy) in USA (PO) (NCT02936752)
  • 02 Oct 2016 Syndax Pharmaceuticals plans a three-stage phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02922933)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top